Intravenous immunoglobulin in severe Crimean-Congo hemorrhagic fever: A retrospective study

AKSOY F., Parlayan H. N. K., Yilmaz D. C., Kizilhan F. A., YILMAZ G.

Asian Pacific Journal of Tropical Medicine, cilt.19, sa.2, ss.73-81, 2026 (SCI-Expanded, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 2
  • Basım Tarihi: 2026
  • Doi Numarası: 10.4103/apjtm.apjtm_449_25
  • Dergi Adı: Asian Pacific Journal of Tropical Medicine
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.73-81
  • Anahtar Kelimeler: Clinical improvement, Crimean-Congo hemorrhagic fever, Intravenous immunoglobulin, Treatment
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Objective: To assess the effectiveness of intravenous immunoglobulin (IVIg) therapy in patients diagnosed with CrimeanCongo hemorrhagic fever (CCHF) disease. Methods: A single-center retrospective cohort study was conducted on hospitalized patients with confirmed severe CCHF at a tertiary care hospital in Turkey between 2010 and 2022. Cases were categorized into two groups based on whether they received IVIg therapy, with the treatment plan determined by the primary healthcare provider. The clinical, epidemiological, and laboratory parameters of these patients were evaluated. Demographic, laboratory findings, platelet counts on the day of IVIg indication and the third day, bleeding status during follow-up beyond 24 hours after IVIg administration, and prognosis recorded in patient information forms were retrieved. Results: 72 patients were included in the analysis, with IVIg administered to 42 cases (58.3%) and not given to 30 cases (41.7%). Among the patients, 37 (51.4%) were female. Fever (65.3%) was the most common clinical presentation. The overall mortality rate was 19.4%, and IVIg administration did not significantly impact overall survival outcomes (P=0.48). On Day 3 following IVIg administration or indication, the platelet count was higher in the IVIg-treated group compared to the non-treated group (P=0.02). Furthermore, during follow-up beyond 24 hours after IVIg administration, bleeding was observed in 19.0% of the IVIg-treated group, compared to 46.6% in the non-treated group (P=0.01). Conclusions: This study underscores the potential advantages of IVIg therapy in managing severe CCHF. Although IVIg administration did not significantly affect overall survival, it was associated with earlier improvement in platelet counts and a notable reduction in bleeding complications. These findings indicate that IVIg may serve as an adjunctive treatment in CCHF, particularly for addressing hemorrhagic manifestations.